Sakamoto Junichi, Ozawa Heita, Nakanishi Hiroki, Toyota Naoyuki, Fujita Shin
Dept. of Colorectal Surgery, Tochigi Cancer Center.
Gan To Kagaku Ryoho. 2022 May;49(5):553-556.
To investigate the efficacy and toxicity of adjuvant chemotherapy(AC)in elderly patients with Stage Ⅲ colorectal cancer(CRC).
We performed a single-institutional retrospective analysis of 84 patients aged≥75 years with Stage Ⅲ CRC who underwent curative resection from August 2009 to February 2018.
Thirty-seven(44.0%) patients received AC. Eleven(29.7%)patients required dose reduction at the start of AC. Twenty-three(62.2%)patients accomplished AC, and 13(35.1%)needed dose reduction during AC. Although toxicities of Grade 3 or higher occurred in 56.8% of patients, they were controllable. The 3-year recurrence-free survival rate was significantly better in the AC group than in the non-AC group(70.3% versus 50.5%, respectively; p=0.011). The prognosis tended to be worse in the group that started AC with dose reduction than in the group with the normal dose.
AC is effective and well tolerated in elderly patients with Stage Ⅲ CRC. When reducing the initial dose, the need for dose reduction should be carefully considered.
探讨辅助化疗（AC）在老年Ⅲ期结直肠癌（CRC）患者中的疗效和毒性。
我们对2009年8月至2018年2月期间接受根治性切除的84例年龄≥75岁的Ⅲ期CRC患者进行了单机构回顾性分析。
37例（44.0%）患者接受了AC。11例（29.7%）患者在AC开始时需要降低剂量。23例（62.2%）患者完成了AC，13例（35.1%）患者在AC期间需要降低剂量。尽管3级或更高等级的毒性发生在56.8%的患者中，但它们是可控的。AC组的3年无复发生存率显著优于非AC组（分别为70.3%和50.5%；p = 0.011）。开始AC时降低剂量的组的预后往往比正常剂量组更差。
AC在老年Ⅲ期CRC患者中有效且耐受性良好。在降低初始剂量时，应仔细考虑降低剂量的必要性。
